To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
REUTERS/Peter Nicholls/File Photo A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019.
Jiji Press
15:43 JST, August 29, 2023
TOKYO (Jiji Press) — A health ministry panel Monday agreed to approve a vaccine developed by GSK PLC to protect people from the respiratory syncytial virus (RSV).
If the British pharmaceutical firm’s vaccine is formally approved, it will be the first for RSV available in Japan.
People eligible for the vaccination will be those aged 60 or older.
The main symptoms of RSV are fever and runny nose. RSV can cause pneumonia and bronchitis in infants and elderly people with underlying conditions.
The virus can be transmitted through contact or droplets, but there is no specific treatment for it.
The number of RSV infection cases in Japan grew briefly around May, when the country downgraded COVID-19 to a lower-risk category of infectious diseases. GSK said the vaccine was 82.6% effective in clinical trials with people aged 60 and older.
U.S. rival Pfizer Inc. has also filed for Japanese regulatory approval of an RSV vaccine.
